ABIOMED, Inc. (NASDAQ:ABMD) VP Andrew J. Greenfield sold 20,000 shares of the stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $270.36, for a total value of $5,407,200.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Shares of ABIOMED, Inc. (ABMD) traded down $4.28 during trading on Thursday, hitting $263.97. 640,131 shares of the stock traded hands, compared to its average volume of 446,028. The firm has a market capitalization of $11,670.00, a P/E ratio of 107.30, a price-to-earnings-growth ratio of 3.59 and a beta of 0.36. ABIOMED, Inc. has a twelve month low of $114.28 and a twelve month high of $274.00.
ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.20. The business had revenue of $154.00 million for the quarter, compared to the consensus estimate of $154.00 million. ABIOMED had a net margin of 16.58% and a return on equity of 15.54%. ABIOMED’s quarterly revenue was up 34.9% on a year-over-year basis. During the same quarter last year, the company posted $0.34 earnings per share. analysts expect that ABIOMED, Inc. will post 2.39 EPS for the current year.
Several equities analysts have commented on ABMD shares. Zacks Investment Research upgraded ABIOMED from a “sell” rating to a “buy” rating and set a $203.00 price target on the stock in a report on Monday, October 30th. Jefferies Group increased their price target on ABIOMED to $250.00 and gave the company a “buy” rating in a report on Friday, January 12th. SunTrust Banks reiterated a “buy” rating and set a $195.00 price target on shares of ABIOMED in a report on Wednesday, November 1st. Piper Jaffray Companies increased their price target on ABIOMED to $200.00 and gave the company an “overweight” rating in a report on Thursday, October 26th. Finally, BidaskClub upgraded ABIOMED from a “hold” rating to a “buy” rating in a report on Thursday, January 11th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $288.86.
Institutional investors have recently made changes to their positions in the company. Lord Abbett & CO. LLC grew its stake in shares of ABIOMED by 282.5% in the second quarter. Lord Abbett & CO. LLC now owns 60,882 shares of the medical equipment provider’s stock worth $8,724,000 after acquiring an additional 44,967 shares during the last quarter. State of Tennessee Treasury Department acquired a new stake in shares of ABIOMED in the third quarter worth $5,058,000. Pratt Collard Advisory Partners LLC acquired a new stake in shares of ABIOMED in the fourth quarter worth $412,000. Hamilton Lane Advisors LLC grew its stake in shares of ABIOMED by 50.8% in the fourth quarter. Hamilton Lane Advisors LLC now owns 23,241 shares of the medical equipment provider’s stock worth $4,356,000 after acquiring an additional 7,827 shares during the last quarter. Finally, Janney Montgomery Scott LLC grew its stake in shares of ABIOMED by 46.3% in the third quarter. Janney Montgomery Scott LLC now owns 2,903 shares of the medical equipment provider’s stock worth $489,000 after acquiring an additional 919 shares during the last quarter. Institutional investors and hedge funds own 86.99% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “ABIOMED, Inc. (ABMD) VP Andrew J. Greenfield Sells 20,000 Shares” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/22/abiomed-inc-abmd-vp-andrew-j-greenfield-sells-20000-shares.html.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.